Compare CCB & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | TNDM |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2018 | 2013 |
| Metric | CCB | TNDM |
|---|---|---|
| Price | $75.88 | $16.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $126.67 | $28.00 |
| AVG Volume (30 Days) | 84.1K | ★ 2.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $96.61 | $8.11 |
| Revenue Next Year | $22.66 | $11.85 |
| P/E Ratio | $98.14 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $66.50 | $10.00 |
| 52 Week High | $120.05 | $29.65 |
| Indicator | CCB | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 48.09 |
| Support Level | $73.44 | $11.86 |
| Resistance Level | $79.50 | $20.79 |
| Average True Range (ATR) | 2.20 | 1.06 |
| MACD | 0.75 | -0.08 |
| Stochastic Oscillator | 77.40 | 33.55 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.